178949-36-5

Upstream product

• 178949-33-2 14-Carbomethoxy-18-nor-20-desoxycamptothecin 
• 178949-32-1 4-Methyl-3,6,10-trioxo-3,4,6,7,8,10-hexahydro-1H-pyrano[3,4-f]indolizine-5-carboxylic acid methyl ester 
• 178949-28-5 6-Bromo-1-hydroxy-7-methoxycarbonylmethyl-5-oxo-1,2,3,5-tetrahydro-indolizine-8-carboxylic acid methyl ester 
• 178949-29-6 1-Hydroxy-7-methoxycarbonylmethyl-5-oxo-6-vinyl-1,2,3,5-tetrahydro-indolizine-8-carboxylic acid methyl ester 
• 159021-82-6 6-Hydroxy-4-methyl-3,10-dioxo-3,4,6,7,8,10-hexahydro-1H-pyrano[3,4-f]indolizine-5-carboxylic acid methyl ester 
• 178949-26-3 1-Hydroxy-7-methoxycarbonylmethyl-5-oxo-1,2,3,5-tetrahydro-indolizine-8-carboxylic acid methyl ester 
• 159021-78-0 Acetic acid 2-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylidene)-pyrrolidin-3-yl ester 
• 159021-79-1 [3-Hydroxy-pyrrolidin-(2Z)-ylidene]-acetic acid methyl ester 
• 34837-55-3 Phenylselenyl bromide 
• 178949-35-4 18-Nor-20-desoxycamptothecin 

Relevant academic research and scientific papers

Synthesis of 18-Noranhydrocamptothecin Analogs Which Retain Topoisomerase I Inhibitory Function

The total syntheses of compounds 2 and 3 are described.Key departures from previous routes to camptothecin from these laboratories involved (i) early incorporation of C2 oxygen (see compound 9) and (ii) recourse to a Heck vinylation for installation of a hydroxymethyl equivalent on the pyridone (see transformation 15 -> 16).The final compounds are of considerable interest in that they are the most drastically modified E ring systems which retain topoisomerase I inhibitory function.